Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Suppressing HIV Infection with Soybean Compound

By BiotechDaily International staff writers
Posted on 14 Aug 2013
A compound found in soybeans may become an effective HIV treatment, which could eliminate the drug resistance problems faced by current therapies, according to new research.

Genistein, derived from soybeans and other plants, shows potential in suppressing the HIV infection, according to Dr. Yuntao Wu, an infectious diseases and the department of molecular and microbiology professor with the George Mason University (Fairfax, VA, USA)-based US National Center for Biodefense.

Nevertheless, that does not mean individuals should begin eating large amounts of soy products. “Although genistein is rich in several plants such as soybeans, it is still uncertain whether the amount of genistein we consume from eating soy is sufficient to inhibit HIV,” Dr. Wu said.

Genistein functions by blocking the communication from a cell’s surface sensors to its insides and is known as a tyrosine kinase inhibitor. These sensors, located on the cell’s surface, tell the cell about its environment and also communicate with other cells. HIV uses some of these surface sensors to trick the cell to send signals inside. These signals change cell structure so that the virus can get inside and spread infection.

However, genistein blocks the signal and stops HIV from finding a way inside the cell. It takes a different approach than the conventional antiretroviral drug used to suppress HIV. “Instead of directly acting on the virus, genistein interferes with the cellular processes that are necessary for the virus to infect cells,” Dr. Wu noted. “Thus, it makes the virus more difficult to become resistant to the drug. Our study is currently it its early stage. If clinically proven effective, genistein may be used as a complement treatment for HIV infection.”

Dr. Wu sees possibilities in this plant-based approach, which may address drug toxicity issues as well. Because genistein is plant-derived, it may be able to sidestep drug toxicity, a common byproduct of the daily and lifelong pharmaceutical regimen faced by patients with HIV to keep the disease at bay, according to Dr. Wu. Typically, patients take a combination of multiple drugs to inhibit the virus. The frequency can lead to drug toxicity. Furthermore, HIV mutates and becomes drug-resistant.

Dr. Wu and his team are now looking for ways to determine how much genistein is required to inhibit HIV. Because there is a possibility that plants may not have high enough levels, this agent would need to be refined and further developed.

Related Links:

George Mason University



view channel
Image: Micrograph showing immunofluorescence of skin differentiation markers for basal keratinocytes (Photo courtesy of Dr. Russ Carstens, University of Pennsylvania).

Alternate Splicing Proteins Critically Linked to Skin and Organ Development

Two proteins that regulate alternative splicing in epithelial cells have been linked to the proper development of the skin and protective layers that surround other organs in the body. Two steps are... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.